Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 14%
Hold 0%
Sell 14%
Strong Sell 0%

Bulls say

Liquidia is a promising company with a strong focus on developing and commercializing innovative and novel medications to address unmet patient needs in the field of pulmonary hypertension (PH) and PH associated with interstitial lung disease. The company's proprietary PRINT technology, a particle engineering platform, allows for precise and uniform production of drug particles, giving them an advantage in the market. Furthermore, their lead product Yutrepia has shown strong performance in the market and is expected to reach blockbuster status. With a large, underpenetrated market and a differentiated technology, we believe Liquidia is well positioned for growth and have a positive outlook on the company's stock.

Bears say

Liquidia is currently facing legal challenges surrounding their product Yutrepia, with the recent Supreme Court ruling validating the possibility of a narrow label-based outcome, although the situation remains different from the Amarin v. Hikma case due to Yutrepia already being approved and marketed for the same indications as competing products. Despite this, Liquidia has reported strong sales and prescription growth for Yutrepia, but there is uncertainty surrounding the company's exclusivity and potential competition in the future. As a result, the current risk environment for Liquidia remains high, with legal decisions potentially impacting the company's financial performance.

LQDA has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 7 analysts, LQDA has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.